scispace - formally typeset
Search or ask a question
Journal Article•DOI•

Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting

Phillip Read1, Rebecca Lothian, Karen J. Chronister1, Rosie Gilliver, John Kearley, Gregory J. Dore2, Gregory J. Dore1, Ingrid van Beek1 •
Kirby Institute1, St. Vincent's Health System2
01 Sep 2017-International Journal of Drug Policy (Elsevier)-Vol. 47, pp 209-215
TL;DR: This study confirms that PWID can be successfully treated for HCV in a real-world setting using an integrated primary health care model and demonstrates feasibility to upscale DAA therapy in high-risk PWID populations, with potential individual and population-level public health benefits.
About: This article is published in International Journal of Drug Policy.The article was published on 2017-09-01. It has received 130 citations till now. The article focuses on the topics: Drug injection & Hepatitis C.
Citations
More filters
Journal Article•DOI•
EASL Recommendations on Treatment of Hepatitis C

[...]

Jean-Michel Pawlotsky, Alessio Aghemo, Geoffrey Dusheiko, Xavier Forns, Massimo Puoti, Christophe Sarrazin 
01 Aug 2018-Journal of Hepatology
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.

2,491 citations

Journal Article•DOI•
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

[...]

Marc G. Ghany1, Timothy R. Morgan2•
National Institutes of Health1, Veterans Health Administration2
01 Feb 2020-Hepatology
TL;DR: The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) initiated the hepatitis C virus guidance project (hereafter HCV guidance) in 2013 and disseminates up-to-date, peer-reviewed, unbiased, evidence-based recommendations to aid clinicians making decisions regarding the testing, management, and treatment of HCV infection.

454 citations

Cites background from "Delivering direct acting antiviral ..."

  • ...Several studies demonstrate that treatment-committed individuals in this disproportionately affected population achieve sustained virologic response (SVR) rates with DAA therapy comparable to those without known, current substance use.(73,132-139) The universal treatment recommendation represents a principal tenet of the HCV guidance along with newly recommended universal hepatitis C screening of adults....

    [...]

Journal Article•DOI•
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

[...]

Jason Grebely1, Olav Dalgard2, Brian Conway, Evan B Cunningham1, Philip Bruggmann, Behzad Hajarizadeh1, Janaki Amin1, Janaki Amin3, Julie Bruneau4, Margaret Hellard5, Margaret Hellard6, Alain H. Litwin7, Philippa Marks1, Sophie Quiene1, Sharmila Siriragavan1, Tanya L. Applegate1, Tracy Swan, Jude Byrne, Melanie Lacalamita8, Adrian Dunlop, Gail V. Matthews9, Gail V. Matthews1, Jeff Powis, David R. Shaw10, Maria Christine Thurnheer8, Martin Weltman11, Ian Kronborg, Curtis Cooper12, Jordan J. Feld13, Christopher S. Fraser, John F. Dillon14, Phillip Read1, Edward Gane15, Gregory J. Dore9, Gregory J. Dore1 •
Kirby Institute1, Akershus University Hospital2, Macquarie University3, Université de Montréal4, Alfred Hospital5, Burnet Institute6, Albert Einstein College of Medicine7, University of Bern8, St. Vincent's Health System9, Royal Adelaide Hospital10, Nepean Hospital11, Ottawa Hospital Research Institute12, Toronto General Hospital13, University of Dundee14, Auckland City Hospital15
01 Mar 2018-The Lancet Gastroenterology & Hepatology
TL;DR: HCV treatment should be offered to PWID, irrespective of ongoing drug use, and recent injection drug use should not be used as a reason to withhold reimbursement of HCV therapy.

220 citations

Journal Article•DOI•
Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis

[...]

Behzad Hajarizadeh1, Evan B Cunningham1, Hannah Reid1, Matthew Law1, Gregory J. Dore1, Jason Grebely1 •
Kirby Institute1
01 Nov 2018-The Lancet Gastroenterology & Hepatology
TL;DR: Responsibility to DAA therapy was favourable among people with recent drug use (including those who inject) and those receiving opioid substitution therapy, supporting broadening access in these populations.

171 citations

Journal Article•DOI•
The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations

[...]

Jeffrey V. Lazarus1, Kelly Safreed-Harmon1, Mark Thursz2, John F. Dillon3, Manal H El-Sayed4, Ahmed M. Elsharkawy, Angelos Hatzakis5, Michel Jadoul6, Tullio Prestileo, Homie Razavi, Jürgen K. Rockstroh7, Stefan Wiktor8, Massimo Colombo •
University of Barcelona1, Imperial College London2, University of Dundee3, Ain Shams University4, National and Kapodistrian University of Athens5, Cliniques Universitaires Saint-Luc6, University of Bonn7, University of Washington8
09 Jul 2018-Seminars in Liver Disease
TL;DR: The introduction of efficacious new hepatitis C virus (HCV) treatments galvanized the World Health Organization to define ambitious targets for eliminating HCV as a public health threat by 2030 through a micro-elimination approach, which entails pursuing elimination goals in discrete populations through multi-stakeholder initiatives that tailor interventions to the needs of these populations.
Abstract: The introduction of efficacious new hepatitis C virus (HCV) treatments galvanized the World Health Organization to define ambitious targets for eliminating HCV as a public health threat by 2030. Formidable obstacles to reaching this goal can best be overcome through a micro-elimination approach, which entails pursuing elimination goals in discrete populations through multi-stakeholder initiatives that tailor interventions to the needs of these populations. Micro-elimination is less daunting, less complex, and less costly than full-scale, country-level initiatives to eliminate HCV, and it can build momentum by producing small victories that inspire more ambitious efforts. The micro-elimination approach encourages stakeholders who are most knowledgeable about specific populations to engage with each other and also promotes the uptake of new models of care. Examples of micro-elimination target populations include medical patients, people who inject drugs, migrants, and prisoners, although candidate populations can be expected to vary greatly in different countries and subnational areas.

169 citations

References
More filters
Journal Article•DOI•
Prospective Comparison of Transient Elastography, Fibrotest, APRI, and Liver Biopsy for the Assessment of Fibrosis in Chronic Hepatitis C

[...]

Laurent Castera, Julien Vergniol, Juliette Foucher, Brigitte Le Bail1, E. Chanteloup, Maud Haaser, Monique Darriet, Patrice Couzigou, Victor de Ledinghen1 •
French Institute of Health and Medical Research1
01 Feb 2005-Gastroenterology
TL;DR: FibroScan is a simple and effective method for assessing liver fibrosis, with similar performance to FibroTest and APRI, and could avoid a biopsy procedure in most patients with chronic hepatitis C.

2,388 citations

"Delivering direct acting antiviral ..." refers methods in this paper

  • ...The cut-off for probable cirrhosis was based on previously published data (Castera et al., 2005)....

    [...]

Journal Article•DOI•
Epidemiology of hepatitis C virus infection

[...]

Miriam J. Alter1•
University of Texas Medical Branch1
07 May 2007-World Journal of Gastroenterology
TL;DR: The wave of increased HCV-related morbidity and mortality that the authors are now facing is the result of an unprecedented increase in the spread of HCV during the 20th century, and two 20th Century events appear to be responsible; the widespread availability of injectable therapies and the illicit use of injectables.
Abstract: Globally, hepatitis C virus (HCV) has infected an estimated 130 million people, most of whom are chronically infected. HCV-infected people serve as a reservoir for transmission to others and are at risk for developing chronic liver disease, cirrhosis, and primary hepatocellular carcinoma (HCC). It has been estimated that HCV accounts for 27% of cirrhosis and 25% of HCC worldwide. HCV infection has likely been endemic in many populations for centuries. However, the wave of increased HCV-related morbidity and mortality that we are now facing is the result of an unprecedented increase in the spread of HCV during the 20th century. Two 20th century events appear to be responsible for this increase; the widespread availability of injectable therapies and the illicit use of injectable drugs.

1,153 citations

Journal Article•DOI•
Declaration of alma-ata

[...]

N.R.E. Fendall
16 Dec 1978-The Lancet

1,126 citations

Journal Article•DOI•
Declaration of alma-ata

[...]

T.C Beard, StephenR. Redmond
27 Jan 1979-The Lancet

515 citations

"Delivering direct acting antiviral ..." refers result in this paper

  • ...Elimination of HCV as a public health threat by 2030 (World Health Organization, 2016) will not be possible without a major focus on DAA access and optimised outcomes within PWID populations....

    [...]

  • ...…to being accessible, affordable, equitable, and acceptable in accordance with World Health Organization’s primary health care philosophy (World Health Organization, 1978) was able to readily accommodate evidence based recommendations for the delivery of HCV care in PWID (Grebely et al., 2015)....

    [...]

  • ...Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting Phillip Reada,b,*, Rebecca Lothiana, Karen Chronistera,b, Rosie Gillivera, John Kearleya, Gregory J. Doreb,c, Ingrid van Beeka,b aKirketon Road Centre, South Eastern Sydney Local Health District, Sydney, Australia bKirby Institute, UNSW Sydney, Sydney, Australia c St Vincent’s Hospital, Sydney, Australia A R T I C L E I N F O Article history: Received 11 January 2017 Received in revised form 28 April 2017 Accepted 8 May 2017 Available online xxx Keywords: Hepatitis C Treatment Antivirals People who inject drugs Targeted primary health care Harm reduction A B S T R A C T Background: The Kirketon Road Centre (KRC) is a community-based public health facility in Sydney, Australia, that provides healthcare to people who inject drugs (PWID) care, including hepatitis C virus (HCV) treatment....

    [...]

  • ...KRC’s targeted primary health care model, with its explicit commitment to being accessible, affordable, equitable, and acceptable in accordance with World Health Organization’s primary health care philosophy (World Health Organization, 1978) was able to readily accommodate evidence based recommendations for the delivery of HCV care in PWID (Grebely et al., 2015)....

    [...]

  • ...This study was approved by the South Eastern Sydney Local Health District Human Research and Ethics committee....

    [...]

Journal Article•DOI•
Hepatitis C Virus Treatment for Prevention Among People Who Inject Drugs: Modeling Treatment Scale-Up in the Age of Direct-Acting Antivirals

[...]

Natasha K. Martin1, Peter Vickerman2, Jason Grebely3, Margaret Hellard4, Sharon J. Hutchinson, Viviane D. Lima, Graham R. Foster, John F. Dillon, David J. Goldberg5, Gregory J. Dore3, Matthew Hickman •
University of Bristol1, University of London2, University of New South Wales3, Burnet Institute4, Health Protection Scotland5
01 Nov 2013-Hepatology
TL;DR: In this article, the authors projected the potential impact of interferon-free direct-acting antiviral (DAA) treatments on hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) in three settings.

456 citations

Related Papers (5)
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

[...]

01 Nov 2016-Annals of Internal Medicine
Gregory J. Dore, Frederick L. Altice, Alain H. Litwin, Olav Dalgard, Edward Gane, Oren Shibolet, Anne F Luetkemeyer, Ronald Nahass, Cheng Yuan Peng, Brian Conway, Jason Grebely, Anita Y. M. Howe, I.N. Gendrano, Erluo Chen, Hsueh Cheng Huang, Frank J. Dutko, David C. Nickle, Bach-Yen Nguyen, Janice Wahl, Eliav Barr, Michael N. Robertson, Heather L. Platt 
Hepatitis C Virus Treatment for Prevention Among People Who Inject Drugs: Modeling Treatment Scale-Up in the Age of Direct-Acting Antivirals

[...]

01 Nov 2013-Hepatology
Natasha K. Martin, Peter Vickerman, Jason Grebely, Margaret Hellard, Sharon J. Hutchinson, Viviane D. Lima, Graham R. Foster, John F. Dillon, David J. Goldberg, Gregory J. Dore, Matthew Hickman 
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.

[...]

04 Aug 2015-Annals of Internal Medicine
Soumitri Barua, Robert Greenwald, Jason Grebely, Gregory J. Dore, Tracy Swan, Lynn E. Taylor 
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

[...]

01 Mar 2017-The Lancet Gastroenterology & Hepatology
Sarah Blach, Stefan Zeuzem, Michael Manns  +219 more
EASL Recommendations on Treatment of Hepatitis C

[...]

01 Aug 2018-Journal of Hepatology
Jean-Michel Pawlotsky, Alessio Aghemo, Geoffrey Dusheiko, Xavier Forns, Massimo Puoti, Christophe Sarrazin